Patents Assigned to Codexis, Inc.
-
Patent number: 11970722Abstract: The present invention provides engineered acid alpha-glucosidase (GAA) polypeptides and compositions thereof. In some embodiments, the engineered GAA polypeptides have been optimized to provide increased expression, stability at neutral pH, and activity in cell lysates. The invention also provides methods for utilization of the compositions comprising the engineered GAA polypeptides for therapeutic and other purposes.Type: GrantFiled: December 18, 2020Date of Patent: April 30, 2024Assignee: Codexis, Inc.Inventors: William Casey Hallows, Rachel Cathleen Botham, Yu Zhu, Chinping Chng, Nikki Dellas, Gjalt W. Huisman, Moulay Hicham Alaoui Ismaili, David William Homan, Adam P. Silverman, Jonathan Vroom, Jessica P. Lao
-
Patent number: 11965192Abstract: The present invention provides engineered penicillin G acylase (PGA) enzymes having improved properties, polynucleotides encoding such enzymes, compositions including the enzymes, and methods of using the enzymes.Type: GrantFiled: November 30, 2021Date of Patent: April 23, 2024Assignee: Codexis, Inc.Inventors: Jovana Nazor, Vesna Mitchell, David Elgart, Katrina W. Lexa, Nikki Dellas, Robert Kevin Orr, Oscar Alvizo, Ravi David Garcia, Judy Victoria Antonio Viduya, Courtney Dianne Moffett
-
Patent number: 11965194Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize chiral compounds.Type: GrantFiled: July 21, 2022Date of Patent: April 23, 2024Assignee: Codexis, Inc.Inventors: Jack S. Liang, Stephan Jenne, Emily Mundorff, Rama Voladri, James J. Lalonde, Gjalt W. Huisman
-
Patent number: 11959108Abstract: The present invention provides engineered protease polypeptides and compositions thereof. The engineered protease polypeptides have been optimized to provide improved activity, improved thermostability, protease stability, autolytic stability, and stability under a range of pH conditions, including acidic (pH<7) and basic (pH>7) conditions. The invention also relates to the use of the compositions comprising the engineered protease polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered protease polypeptides, as well as methods for making the engineered polynucleotides and protease polypeptides.Type: GrantFiled: August 27, 2021Date of Patent: April 16, 2024Assignees: Codexis, Inc., Societe des Produits Nestle S.A.Inventors: Chinping Chng, Nikki Dellas, Ravi David Garcia, Moulay Hicham Alaoui Ismaili, Kristen Jean Vallieu, Kerryn McCluskie
-
Patent number: 11926857Abstract: The present disclosure provides acyltransferases useful for synthesizing therapeutically important statin compound.Type: GrantFiled: May 25, 2021Date of Patent: March 12, 2024Assignee: Codexis, Inc.Inventors: Lynne Gilson, Steven J. Collier, Joly Sukumaran, Wan Lin Yeo, Oscar Alvizo, Ee Ling Teo, Robert J. Wilson, Junye Xu
-
Patent number: 11913045Abstract: The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides.Type: GrantFiled: September 2, 2020Date of Patent: February 27, 2024Assignee: Codexis, Inc.Inventors: Gjalt W. Huisman, Nicholas J. Agard, Benjamin Mijts, Jonathan Vroom, Xiyun Zhang
-
Patent number: 11913037Abstract: The present invention provides engineered adenylate kinase (AdK) enzymes, polypeptides having AdK activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing AdK enzymes are also provided. The present invention further provides compositions comprising the AdK enzymes and methods of using the engineered AdK enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: GrantFiled: April 1, 2022Date of Patent: February 27, 2024Assignee: Codexis, Inc.Inventors: Da Duan, Auric Anthony Sowell-Kantz, Aksiniya Lyubenova Petkova, Oscar Alvizo
-
Patent number: 11913036Abstract: The present invention provides engineered acetate kinase (AcK) enzymes, polypeptides having AcK activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing AcK enzymes are also provided. The present invention further provides compositions comprising the AcK enzymes and methods of using the engineered AcK enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: GrantFiled: April 1, 2022Date of Patent: February 27, 2024Assignee: Codexis, Inc.Inventors: Margie Tabuga Borra-Garske, Oscar Alvizo, Lillian Jasmine Miller, Aksiniya Lyubenova Petkova
-
Patent number: 11898174Abstract: The present invention provides engineered uridine phosphorylase (UP) enzymes, polypeptides having UP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing UP enzymes are also provided. The present invention further provides compositions comprising the UP enzymes and methods of using the engineered UP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: GrantFiled: December 17, 2021Date of Patent: February 13, 2024Assignee: Codexis, Inc.Inventors: Jonathan Vroom, Jessica Anna Hurtak, Anders Matthew Knight
-
Patent number: 11845968Abstract: The present invention provides engineered deoxyribose-phosphate aldolase polypeptides useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds.Type: GrantFiled: February 4, 2022Date of Patent: December 19, 2023Assignee: Codexis, Inc.Inventors: Da Duan, Oscar Alvizo, Jovana Nazor, Harvinder Chagger Maniar, James Nicholas Riggins, Jonathan Vroom, Santhosh Sivaramakrishnan, Hao Yang, Anna Fryszkowska, Mark A. Huffman, Joshua N. Kolev, Iman Farasat, Agustina Rodriguez-Granillo, Deeptak Verma
-
Patent number: 11807874Abstract: The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.Type: GrantFiled: February 15, 2022Date of Patent: November 7, 2023Assignee: Codexis, Inc.Inventors: Robert Osborne, Vesna Mitchell, Khin Yu Naing Htwe, Xiyun Zhang, Erika M. Milczek, Jeffrey C. Moore
-
Patent number: 11802274Abstract: The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.Type: GrantFiled: May 6, 2022Date of Patent: October 31, 2023Assignee: Codexis, Inc.Inventors: Oscar Alvizo, Melissa Ann Mayo, Jeffrey C. Moore
-
Patent number: 11795445Abstract: The present invention provides engineered phosphopentomutase (PPM) enzymes, polypeptides having PPM activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PPM enzymes are also provided. The present invention further provides compositions comprising the PPM enzymes and methods of using the engineered PPM enzymes. The present invention finds particular use in the production of pharmaceutical compounds.Type: GrantFiled: May 10, 2021Date of Patent: October 24, 2023Assignee: Codexis, Inc.Inventors: Scott J. Novick, Xiang Yi, Nikki Dellas, Oscar Alvizo, Jovana Nazor, Da Duan, Vesna Mitchell, Jonathan Vroom, Santhosh Sivaramakrishnan, Nandhitha Subramanian, Jeffrey C. Moore, Mark Huffman, Agustina Rodriguez-Granillo, Deeptak Verma, Grant S. Murphy, Nicholas Marshall, Jay Russell, Keith A. Canada
-
Patent number: 11788071Abstract: The present disclosure provides engineered transaminase polypeptides useful for the synthesis of chiral amine compounds under industrially relevant conditions. The disclosure also provides polynucleotides encoding the engineered transaminase polypeptides, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases for the production of chiral amine compounds.Type: GrantFiled: April 6, 2021Date of Patent: October 17, 2023Assignee: Codexis, Inc.Inventors: Scott J. Novick, Nikki Dellas
-
Patent number: 11767519Abstract: The present invention provides engineered amylase polypeptides and compositions thereof. The engineered amylase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) conditions. The invention also relates to the use of the compositions comprising the engineered amylase polypeptides for therapeutic and/or nutritional purposes. The present invention also provides polynucleotides encoding the engineered amylase polypeptides, as well as methods for making the engineered polynucleotides and amylase polypeptides.Type: GrantFiled: August 27, 2021Date of Patent: September 26, 2023Assignees: Codexis, Inc., Societe des Produits Nestle S.A.Inventors: Chinping Chng, Nikki Dellas, Da Duan, Ravi David Garcia, Harvinder Chagger Maniar
-
Patent number: 11760981Abstract: The present invention provides engineered glycosyltransferase (GT) enzymes, polypeptides having GT activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention provides engineered sucrose synthase (SuS) enzymes, polypeptides having SuS activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention also provides compositions comprising the GT enzymes and methods of using the engineered GT enzymes to make products with ?-glucose linkages. The present invention further provides compositions and methods for the production of rebaudiosides (e.g., rebaudioside M, rebaudioside A, rebaudioside I, and rebaudioside D). The present invention also provides compositions comprising the SuS enzymes and methods of using them. Methods for producing GT and SuS enzymes are also provided.Type: GrantFiled: July 17, 2019Date of Patent: September 19, 2023Assignee: Codexis, Inc.Inventors: Jonathan Vroom, Stephanie Sue Galanie, Jack Liang, Joyce Liu, Nikki Dellas, Melissa Ann Mayo, David Entwistle
-
Patent number: 11746369Abstract: The present invention provides engineered ketoreductase and phosphite dehydrogenase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase and phosphite dehydrogenase enzymes, as well as polynucleotides encoding the engineered ketoreductase and phosphite dehydrogenase enzymes, host cells capable of expressing the engineered ketoreductase and phosphite dehydrogenase enzymes, and methods of using the engineered ketoreductase and phosphite dehydrogenase enzymes to synthesize a chiral catalyst used in the synthesis of antiviral compounds, such as nucleoside inhibitors. The present invention further provides methods of using the engineered enzymes to deracemize a chiral alcohol in a one-pot, multi-enzyme system.Type: GrantFiled: April 26, 2021Date of Patent: September 5, 2023Assignee: Codexis, Inc.Inventors: Jeffrey C. Moore, Jack Liang, Jonathan Penfield, Jovana Nazor, Nikki Dellas, Vesna Mitchell, Da Duan, Iman Farasat, Agustina Rodriguez-Granillo, Grant Murphy, Nicholas Marshall
-
Patent number: 11732248Abstract: The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.Type: GrantFiled: May 11, 2021Date of Patent: August 22, 2023Assignee: Codexis, Inc.Inventors: Weng Lin Tang, Helen Hsieh, Son Pham, Derek Smith, Steven J. Collier
-
Patent number: 11725198Abstract: Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease. Further provided herein are pharmaceutical compositions comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof to treat bacterial infections of the gastrointestinal tract, such as C. difficile or H. pylori. Further provided herein are compositions comprising recombinant nepenthesin I or nepenthesin II, or homologous proteins, and methods for making the same.Type: GrantFiled: March 23, 2021Date of Patent: August 15, 2023Assignee: CODEXIS, INC.Inventors: David C. Schriemer, Petr Man, Hynek Mrazek, Martial Rey
-
Patent number: 11723960Abstract: The invention described herein relates to methods and compositions for treatment of gluten intolerance and related conditions (e.g., celiac disease and gluten sensitivity), or inhibition of inflammation and/or immune response in the intestine due to antigenic food peptides, by administration of a pharmaceutical composition comprising one or more Nepenthes enzymes.Type: GrantFiled: February 22, 2021Date of Patent: August 15, 2023Assignee: Codexis, Inc.Inventors: David C. Schriemer, Martial Rey